875148-45-1|Regadenoson hydrate|1-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carboxamide hydrate|-范德生物科技公司

Regadenoson hydrate

NMR下载 COA and HPLC MSDS下载
names：
1-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carboxamide hydrate
CAS号：
875148-45-1
MDL Number：
MF(分子式)： C15H20N8O6 MW(分子量)： 408.37
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	1-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carboxamide hydrate
英文别名	Regadenoson; Lexiscan; Regadenoson hydrate; CVT-3146; CVT 3146; CVT3146;
CAS号	875148-45-1
SMILES	O=C(C1=CN(C2=NC(N)=C3N=CN([C@H]4[C@@H]([C@@H]([C@@H](CO)O4)O)O)C3=N2)N=C1)NC.[H]O[H]
Inchi	InChI=1S/C15H18N8O5.H2O/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14;/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21);1H2/t7-,9-,10-,14-;/m1./s1
InchiKey	CDQVVPUXSPZONN-WPPLYIOHSA-N
分子式 Formula	C15H20N8O6
分子量 Molecular Weight	408.37
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Regadenoson hydrate(CAS:875148-45-1 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Regadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Johnson NP, Gould KL. Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. JACC Cardiovasc Imaging. 2015 Apr;8(4):438-447. doi: 10.1016/j.jcmg.2014.11.016. Epub 2015 Mar 18. PubMed PMID: 25797122.

[2]Mahmarian JJ, Peterson LE, Xu J, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Nabi F. Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials. J Nucl Cardiol. 2015 Apr;22(2):248-61. doi: 10.1007/s12350-014-9981-6. Epub 2014 Oct 7. PubMed PMID: 25287737.

[3] Brink HL, Dickerson JA, Stephens JA, Pickworth KK. Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing. Pharmacotherapy. 2015 Dec;35(12):1117-23. doi: 10.1002/phar.1669. PubMed PMID: 26684552.

[4] Bitar A, Mastouri R, Kreutz RP. Caffeine Consumption and Heart Rate and Blood Pressure Response to Regadenoson. PLoS One. 2015 Jun 22;10(6):e0130487. doi: 10.1371/journal.pone.0130487. eCollection 2015. PubMed PMID: 26098883; PubMed Central PMCID: PMC4476756.

[5] van Nunen LX, Lenders GD, Schampaert S, van 't Veer M, Wijnbergen I, Brueren GR, Tonino PA, Pijls NH. Single bolus intravenous regadenoson injection versus central venous infusion of adenosine for maximum coronary hyperaemia in fractional flow reserve measurement. EuroIntervention. 2015 Dec;11(8):905-13. doi: 10.4244/EIJY14M08_10. PubMed PMID: 25136887.

6: Cury RC, Kitt TM, Feaheny K, Blankstein R, Ghoshhajra BB, Budoff MJ, Leipsic J, Min JK, Akin J, George RT. A randomized, multicenter, multivendor study of myocardial perfusion imaging with regadenoson CT perfusion vs single photon emission CT. J Cardiovasc Comput Tomogr. 2015 Mar-Apr;9(2):103-12.e1-2. doi: 10.1016/j.jcct.2015.01.002. Epub 2015 Jan 7. PubMed PMID: 25726411.7: Prasad A, Zareh M, Doherty R, Gopal A, Vora H, Somma K, Mehra A, Clavijo LC, Matthews RV, Shavelle DM. Use of regadenoson for measurement of fractional flow reserve. Catheter Cardiovasc Interv. 2014 Feb 15;83(3):369-74. doi: 10.1002/ccd.25055. Epub 2013 Jul 3. PubMed PMID: 23765847.8: Cury RC, Kitt TM, Feaheny K, Akin J, George RT. Regadenoson-stress myocardial CT perfusion and single-photon emission CT: rationale, design, and acquisition methods of a prospective, multicenter, multivendor comparison. J Cardiovasc Comput Tomogr. 2014 Jan-Feb;8(1):2-12. doi: 10.1016/j.jcct.2013.09.004. Epub 2013 Oct 18. PubMed PMID: 24314823.9: Saab R, Zouk AN, Mastouri R, Skaar TC, Philips S, Kreutz RP. AMPD1 polymorphism and response to regadenoson. Pharmacogenomics. 2015 Nov;16(16):1807-15. doi: 10.2217/pgs.15.116. Epub 2015 Nov 10. PubMed PMID: 26554440; PubMed Central PMCID: PMC4826562.10: Rangel MO, Morales Demori R, Voll ST, Wassouf M, Dick R, Doukky R. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol. 2015 Oct;22(5):1008-18. doi: 10.1007/s12350-014-0036-9. Epub 2014 Dec 11. PubMed PMID: 25500799.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开